Replication data for: Entry Threats and Pricing in the Generic Drug Industry

Name: Replication data for: Entry Threats and Pricing in the Generic Drug Industry
Creator: Federal Trade Commission
Published: 2014-12-12 00:00:00
License: 暂无描述

Harvard Dataverse2014-12-12 更新2026-04-09 收录

下载链接：

https://dataverse.harvard.edu/citation?persistentId=doi:10.7910/DVN/28098

下载链接

链接失效反馈

官方服务：

资源简介：

Volume 96, Issue 2

提供机构：

Federal Trade Commission

创建时间：

2014-05-01

"Generic Entry and the Pricing of Pharmaceuticals"

During the 1980s the share of prescriptions sold by retail pharmacies that was accounted for by generic products roughly doubled. The price response to generic entry of brand-name products has been a

NBER1995-10-01 更新180

Replication data for: Copyright and Generic Entry in Book Publishing

Taking works off copyright promotes their availability, but it also allows generic entry to dissipate producer surplus. This paper examines the effect of a copyright on the availability and price of b

ICPSR2019-01-01 更新10

Replication data for: Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry

Appelt, Silvia, (2015) \"Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry.\" Review of Economics and Statistics 97:3, 654-666.

DataONE2015-08-31 更新30

Replication data for: Pricing in the Market for Anticancer Drugs

In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab— brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase

ICPSR2015-01-01 更新20

Entry Decisions in the Generic Pharmaceutical Industry

In this paper I use data on all generic drug approvals granted from 1984- 1994 to examine whether heterogeneity among potential generic entrants can be used to predict which firms will choose to enter

NBER1997-09-01 更新30